Cargando…

US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review

BACKGROUND: Black cisgender women in the United States experience a disproportionate burden of human immunodeficiency virus acquisition. Pre-exposure prophylaxis is an effective oral daily medication that reduces the risk of human immunodeficiency virus through sex by 99% when taken as prescribed. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Conley, Cherie, Johnson, Ragan, Bond, Keosha, Brem, Sullivan, Salas, Jasmine, Randolph, Schenita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201306/
https://www.ncbi.nlm.nih.gov/pubmed/35699104
http://dx.doi.org/10.1177/17455057221103098
_version_ 1784728281275170816
author Conley, Cherie
Johnson, Ragan
Bond, Keosha
Brem, Sullivan
Salas, Jasmine
Randolph, Schenita
author_facet Conley, Cherie
Johnson, Ragan
Bond, Keosha
Brem, Sullivan
Salas, Jasmine
Randolph, Schenita
author_sort Conley, Cherie
collection PubMed
description BACKGROUND: Black cisgender women in the United States experience a disproportionate burden of human immunodeficiency virus acquisition. Pre-exposure prophylaxis is an effective oral daily medication that reduces the risk of human immunodeficiency virus through sex by 99% when taken as prescribed. However, less than 2% of eligible Black cisgender women take pre-exposure prophylaxis. The purpose of this scoping review was to describe the types of research studies done in this area, gaps in knowledge, and potential areas of research needed to increase pre-exposure prophylaxis use among Black cisgender women in the United States. METHODS: We conducted our search in MEDLINE (PubMed), Embase (Elsevier), CINAHL (EBSCOhost), PsycINFO (EBSCOhost), and Scopus (Elsevier) using a combination of keywords and database-specific subject headings for the following concepts: pre-exposure prophylaxis, African American/Black or minority, and women. We used the Joanna Briggs Institute’s Reviewers’ Manual process for Scoping Reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews to ensure comprehensive and standardized reporting of each part of the review. RESULTS: Fifty-nine studies were included in the final review. Results of the study were classified according to the three phases of the Human Immunodeficiency Virus Prevention Cascade—demand side, supply side, and adherence and retention. The majority of studies (n = 24, 41%) were cross-sectional quantitative surveys and 43 (34%) focused on the demand-side phase of the Human Immunodeficiency Virus Prevention Cascade. Fifty-eight percent of studies either assessed women’s pre-exposure prophylaxis knowledge, attitudes, and intentions to use, or assessed perceived barriers and facilitators. Seven studies (12%) tested pre-exposure prophylaxis uptake and adherence among Black cisgender women. CONCLUSION: This review found multiple missed opportunities to increase women’s demand for pre-exposure prophylaxis and health care provider screening and referral for pre-exposure prophylaxis. Additional studies are needed to effectively assess pre-exposure prophylaxis uptake and adherence among Black cisgender women.
format Online
Article
Text
id pubmed-9201306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92013062022-06-17 US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review Conley, Cherie Johnson, Ragan Bond, Keosha Brem, Sullivan Salas, Jasmine Randolph, Schenita Womens Health (Lond) Review BACKGROUND: Black cisgender women in the United States experience a disproportionate burden of human immunodeficiency virus acquisition. Pre-exposure prophylaxis is an effective oral daily medication that reduces the risk of human immunodeficiency virus through sex by 99% when taken as prescribed. However, less than 2% of eligible Black cisgender women take pre-exposure prophylaxis. The purpose of this scoping review was to describe the types of research studies done in this area, gaps in knowledge, and potential areas of research needed to increase pre-exposure prophylaxis use among Black cisgender women in the United States. METHODS: We conducted our search in MEDLINE (PubMed), Embase (Elsevier), CINAHL (EBSCOhost), PsycINFO (EBSCOhost), and Scopus (Elsevier) using a combination of keywords and database-specific subject headings for the following concepts: pre-exposure prophylaxis, African American/Black or minority, and women. We used the Joanna Briggs Institute’s Reviewers’ Manual process for Scoping Reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews to ensure comprehensive and standardized reporting of each part of the review. RESULTS: Fifty-nine studies were included in the final review. Results of the study were classified according to the three phases of the Human Immunodeficiency Virus Prevention Cascade—demand side, supply side, and adherence and retention. The majority of studies (n = 24, 41%) were cross-sectional quantitative surveys and 43 (34%) focused on the demand-side phase of the Human Immunodeficiency Virus Prevention Cascade. Fifty-eight percent of studies either assessed women’s pre-exposure prophylaxis knowledge, attitudes, and intentions to use, or assessed perceived barriers and facilitators. Seven studies (12%) tested pre-exposure prophylaxis uptake and adherence among Black cisgender women. CONCLUSION: This review found multiple missed opportunities to increase women’s demand for pre-exposure prophylaxis and health care provider screening and referral for pre-exposure prophylaxis. Additional studies are needed to effectively assess pre-exposure prophylaxis uptake and adherence among Black cisgender women. SAGE Publications 2022-06-14 /pmc/articles/PMC9201306/ /pubmed/35699104 http://dx.doi.org/10.1177/17455057221103098 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Conley, Cherie
Johnson, Ragan
Bond, Keosha
Brem, Sullivan
Salas, Jasmine
Randolph, Schenita
US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title_full US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title_fullStr US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title_full_unstemmed US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title_short US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review
title_sort us black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: a scoping review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201306/
https://www.ncbi.nlm.nih.gov/pubmed/35699104
http://dx.doi.org/10.1177/17455057221103098
work_keys_str_mv AT conleycherie usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview
AT johnsonragan usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview
AT bondkeosha usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview
AT bremsullivan usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview
AT salasjasmine usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview
AT randolphschenita usblackcisgenderwomenandpreexposureprophylaxisforhumanimmunodeficiencyviruspreventionascopingreview